Reports Q4 revenue $11.42B vs. $10.58B last year. Vas Narasimhan, CEO of Novartis, said: “Novartis completed its strategic transformation into a pure-play innovative medicines company and continued its relentless pursuit of sustainable shareholder value creation. Our robust operational performance continues, with strong double-digit top and bottom-line growth, for the quarter and full year. We delivered ten positive Ph3 readouts on assets with significant sales potential, over the past year. The very strong performance of our key growth drivers and pipeline underscores the confidence in our growth – 5% cc CAGR 2023-2028 – and margin – 40%-plus by 2027 – mid-term guidance.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis AG (NVS) Q4 Earnings Cheat Sheet
- Novartis initiated with an Equal Weight at Morgan Stanley
- FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
- OPDP says Novartis’ Kisqali TV ad makes false or misleading representations
- Novartis says Lutathera reduced risk of disease progression, death in study
